Cameco (TSE:CCO) (NYSE:CCJ) had its price target decreased by Eight Capital from C$18.00 to C$17.00 in a research note released on Monday morning, BayStreet.CA reports.
A number of other equities research analysts also recently weighed in on the company. Raymond James reaffirmed a buy rating and set a $21.00 price target on shares of Colfax in a research note on Thursday, May 2nd. TD Securities cut their price target on WPX Energy from $19.00 to $18.50 and set a buy rating for the company in a research note on Thursday, May 2nd. Royal Bank of Canada reaffirmed an average rating and set a $48.00 price target on shares of in a research note on Thursday, June 27th. Finally, BMO Capital Markets started coverage on Encompass Health in a research note on Thursday, June 27th. They set an outperform rating and a $72.00 price target for the company.
CCO opened at C$13.18 on Monday. Cameco has a fifty-two week low of C$12.31 and a fifty-two week high of C$17.12. The business’s 50-day moving average price is C$13.86. The company has a debt-to-equity ratio of 30.16, a current ratio of 2.55 and a quick ratio of 1.66. The stock has a market cap of $5.25 billion and a P/E ratio of 57.30.
Cameco Company Profile
Cameco Corporation produces and sells uranium worldwide. The company operates in two segments, Uranium and Fuel Services. The Uranium segment is involved in the exploration for, mining, and milling, as well as purchase and sale of uranium concentrate. Its operating uranium properties include the Cigar Lake property located in Saskatchewan, Canada; and the Inkai property located in Kazakhstan.
Featured Story: What Does a Sell-Side Analyst Rating Mean?
Receive News & Ratings for Cameco Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cameco and related companies with MarketBeat.com's FREE daily email newsletter.